Sponsored Content for Nativ Segev

ASX-listed MGC Pharmaceuticals has bolstered its European medicinal cannabis growing operations by shifting nearly 500 marijuana plants to the company's facilities in the Czech Republic. MGC is moving full steam ahead with its botanical division, largely based in the EU, after last month receiving a full European licence to grow cannabis.

MGC Pharmaceuticals has signed a distribution deal to supply its medicainal marijuana products across Slovenia, Croatia and Bosnia. The exclusive agreement with leading Slovenian laboratory supplier, Mikro+Polo, builds on positive momentum at MGC after it was given a full European licence to grow and cultivate cannabis this month.

MGC Pharmaceuticals will breed and register new medicinal cannabis strains in Europe under a research partnership with Solvenia's leading university. The new agreement with the University of Ljubljana adds to an impressive bank of medicinal Cannabis research activity by MGC and gives the ASX-listed company a potential inside track to the European market.

An independent clinical trial of MGC Pharma's cannabis-based dermatological creams has produced spectacular results with the trials showing an 80% improvement in acne prone skin, 73% improvement in psoriatic plaques, 86% improvement of irritated skin and over 70% improvement in the visual appearance of redness, dryness, flaky and oily skin conditions.

MGC Pharmaceuticals has cemented its position in the Australian medical marijuana market, signing a major research agreement with the Royal Melbourne Institute of Technology. The deal will see MGC and RMIT collaborate on medical cannabis research initiatives targeted at a range of diseases including cancer and establish an “International Library of Cannabis Medicine”.

Medicinal marijuana player MGC Pharmaceuticals are on a mission to be one of the first ASX listed companies to garner serious revenues from medicinal cannabis derived products. The company announced this week they had signed up wholesalers in Europe to market their cannabis derived skin care and cosmetics lines.

Whilst many other medical marijuana hopefuls are still talking up their opportunities in the industry, Perth listed MGC Pharmaceuticals have produced their first cannabinoid extracts at the company's brand new European extraction facility. The milestone means MGC remains on track for commercial production to commence in the third quarter of this year.

Medicinal cannabis player MGC Pharmaceuticals remains on schedule for its first commercial production of medical marijuana, with the Perth-based company's European cannabis extraction facility completing construction. MGC expects the initial commercial cannabinoid extraction to commence in Q3.

Medicinal cannabis player MGC Pharma has easily raised $10 million as it looks to fast-track acquisitions and accelerate development of its cannabis-derived products. MGC will use the funds to ramp up its medical R&D program and expand sales of its cosmetics and dermatological cannabis-derived lines with the latter to fund the former.

ASX-listed Sky and Space Global says its first three miniature telecommunications satellites known as “nano-satellites” are now ready for launch after the completion of final testing in Europe. The nano-satellites are scheduled for launch on board the Indian Space Research Organisation's Polar Satellite Launch Vehicle in the second quarter of this year.

ASX-listed MGC Pharmaceuticals' cannabis-derived medicinal products will be fast-tracked to Australia following federal government changes to national medical marijuana laws. The changes mean patients that are prescribed medicinal cannabis will be able to import their medication from local providers such as MGC Pharmacueticals.

ASX-listed MGC Pharmaceuticals are on schedule to complete a major commercial and operational milestone, with their medical grade cannabis extraction facility nearing completion in Slovenia. The new facility will allow the Perth-based company to ramp up its production of cannabis derivative cannabidiol to 3,000kg per year.

In a bold move, ASX-listed MGC Pharmaceuticals has announced it will undertake a new clinical trial to detremine how medicinal cannabis could potentially treat young epilepsy sufferers. The Perth-based company believes the study could present a significant commercial opportunity in the medical marijuana space and it may add a third revenue stream for the company.

ASX-listed MGC Pharmaceuticals has completed the acquisition of Czech-based medical cannabis company Panax Pharma. The deal will boost MGC's research capabilities by giving the company access to leading growing and research facilities in the Czech Republic. MGC said it had settled on a binding heads of agreement to acquire up to 100 per cent equity in Panax.

ASX-listed MGC Pharmaceuticals march towards full commercialisation of its cannabis-based dermatological skin care line is a step closer with the company announcing the start of human clinical trials of its products. The company says it plans to commence sales of its unique derma skin care range that will target acne amongst other things from September.

Medical marijuana company MGC Pharma has been given the tick of approval to sell its brand new cannabis-based dermatological skincare range in the European Union. MGC sees the green light from the European Cosmetics Products Notifications Portal as a major step forward for its new skin care range that will treat acne, psoriasis and seborrhoea.

ASX-listed MGC Pharmaceuticals says it is on schedule to commence production of research grade cannabis by mid-2017 after harvesting its first crop at its Slovenian facilities. In a strong finish to 2016, the company has also confirmed the execution of its deal to acquire Czech-based medical cannabis company Panax Pharma on more favourable terms.

In a move that is likely to ramp up its production and research capabilities, MGC Pharmaceuticals has signed a new, renegotiated, binding heads of agreement to acquire Czech-based medical cannabis company Panax Pharma. Under the deal, the Perth-based company will gain access to world-leading facilities in the Czech Republic for its medical cannabis research.

Whilst most medical Marijuana companies are still trying to work out how to monetize their businesses, MGC Pharmaceuticals are busy locking down international distribution deals with real revenue flows for their unique, Cannabis based skin care line, MGC Derma. The company announced last week it had secured its first major sales order worth around AUD$65,000.